Skip to content

Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries

A Cluster Randomized Clinical Trial of Umbilical Cord Milking Versus Early Cord Clamping on Short and Long-term Outcomes in Neonates Who Are Non-Vigorous at Birth

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03657394
Acronym
CORDMILK
Enrollment
3442
Registered
2018-09-05
Start date
2022-10-17
Completion date
2026-10-31
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birth Asphyxia, Hypoxic-Ischemic Encephalopathy

Keywords

Placental transfusion

Brief summary

The investigators will conduct a study on non-vigorous infants at birth to determine if umbilical cord milking (UCM) results in lower rate of moderate to severe hypoxic ischemic encephalopathy (HIE) or death than early clamping and for infants who are non-vigorous at birth and need immediate resuscitation.

Detailed description

Hypoxic-ischemic encephalopathy (HIE) is a brain injury caused by inadequate blood flow and oxygen delivery to the neonatal brain. Almost all infants with severe HIE and 30-50% infants with moderate HIE either die or develop significant developmental delay, cerebral palsy or other disabilities.The incidence of HIE is 1-3 per 1,000 term births in developed countries and 15-20 times higher in developing countries (Worldwide, 0.5 to 1 million infants develop HIE each year). Therapeutic hypothermia is the only proven therapy for infants with HIE. Even after receiving therapeutic hypothermia, one-half of all infants with moderate and severe HIE die or develop neurological and functional impairment. Therapeutic hypothermia is not widely available and ineffective in developing nations.There is an urgent need for a new therapy for neonates with HIE, which can complement hypothermia and be readily available in developing nations. Stem cell transplantation is a potential therapy for infants with HIE. Umbilical cord blood is a rich source of stem cells. Umbilical cord milking (UCM) may have similar effect as autologous umbilical cord blood cell transplantation. Preliminary evidence suggests a placental transfusion in term infants may be a neuroprotective mechanism that can also facilitate cardiovascular transition for neonates depressed at birth and result in decreased mortality and improved neurodevelopmental outcomes. Infants with HIE, due to varied complications during the birth process, have poor perfusion due to fetal blood volume loss to the placenta. However, the most common method of providing placental blood, delayed cord clamping (DCC) cannot be performed since infants with HIE are non-vigorous and providers often need to perform resuscitation immediately after birth. The World Health Organization and the American College of Obstetrics and Gynecology (ACOG) also does not recommended DCC in neonates who are non-vigorous (limp, pale, and not breathing) at birth and require immediate resuscitation. Umbilical cord milking (UCM) or gently squeezing cord blood toward the baby, is an alternative to DCC, which can achieve significant placental transfusion without delaying resuscitation. Further, UCM can be completed as quickly as immediate cord clamping (ICC) and UCM requires minimal training and no additional staff. The investigators hypothesized that UCM will reduce the number of infants developing moderate to severe HIE or death in neonates who are non-vigorous at birth compared to early cord clamping (ECC). This will be a cluster crossover randomized controlled trial. Each hospital will be randomly assigned to use either ECC or UCM for any infant who is non-vigorous at birth and needing resuscitation over a period of 6 months. Then the site will change to the other method for an additional 6 months.

Interventions

OTHERUmbilical cord milking

At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.

Sponsors

Nemours Children's Clinic
Lead SponsorOTHER
Sharp HealthCare
CollaboratorOTHER
Thomas Jefferson University
CollaboratorOTHER
University of San Diego
CollaboratorOTHER
St. Louis University
CollaboratorOTHER
Jawaharlal Nehru Medical College
CollaboratorOTHER
Daga Memorial Maternity and Children's Hospital, Nagpur, India
CollaboratorUNKNOWN
Mahatma Gandhi Institute of Medical Sciences
CollaboratorOTHER
Karnataka Institue of Medical Sciences, Hubbali, India
CollaboratorUNKNOWN
Jawaharlal Institute of Postgraduate Medical Education & Research
CollaboratorOTHER_GOV
All India Institute of Medical Sciences
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Indira Gandhi Government Medical College & Hospital, Nagpur, India
CollaboratorUNKNOWN
Pimpri Chinchwad Municipal Corporation's Post-Graduate Institute, Yashwantrao Chavan Memorial Hospital, Pune, India
CollaboratorUNKNOWN
Government Medical College, Nagpur
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Cluster Randomized Crossover

Eligibility

Sex/Gender
ALL
Age
35 Weeks to 42 Weeks
Healthy volunteers
No

Inclusion criteria

* Non-vigorous neonates born between 35-42 weeks

Exclusion criteria

* Congenital malformation of CNS. * Chromosomal abnormalities. * Major congenital malformations. * Abruption/cutting through the placenta at delivery. * Umbilical cord knots or inadequate cord length. * Mono-chorionic twins or twins with no information on amnion/chorion. * Multiple gestation \>2 .

Design outcomes

Primary

MeasureTime frameDescription
Moderate to severe HIE or deathFrom date of birth until the date of discharge from the hospital or date of death from any cause, whichever come first, asessed up to 10 weeks.Number of infants with moderate to severe HIE or death

Secondary

MeasureTime frameDescription
MRI of the brain4 days to 2 weeksNumber of infants with moderate to severe HIE who have abnormal brain MRI

Countries

India

Contacts

PRINCIPAL_INVESTIGATORZubair H Aghai, MD

Nemours Children's Clinic

PRINCIPAL_INVESTIGATORAnup Katheria, MD

Sharp Mary Birch Hospital for Women & Newborns

PRINCIPAL_INVESTIGATORSangappa Dhaded, MD

KLE Academy of Higher Education and Research

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026